Page last checked
Goal
Peptides for sleep
Of these five peptides, DSIP has small studies that measured sleep directly. The other records track hormones or body-clock signals rather than sleep improvement.
Source for this answer
Source: Based on 5 compound guides · checked 2026-09-07
Source: Based on 5 compound guides · checked 2026-09-07
Three compounds—ipamorelin, CJC-1295 and sermorelin—have growth-hormone studies. Epitalon has a study of melatonin-related and body-clock signals. Those measurements do not show whether someone slept better.
DSIP’s sleep studies are small and old. Their routes and settings matter when comparing them with products sold today.
At a glance
Compounds covered
5
FDA-approved for this goal
0
Being tested for this goal
0
Reported use only
4
Five compounds, and what each study measured
DSIP studies measured sleep. The other rows explain which hormone or body-clock measurements were made and why they do not show a sleep benefit.
| Compound | What people take it for | What research shows | Evidence |
|---|---|---|---|
| DSIP | Sold for insomnia and for improving sleep quality.Measured in a human study | European groups gave it through the 1980s to people with insomnia and to people in alcohol and opiate withdrawal, and reported sleep normalizing. One sleep-laboratory study followed 18 chronic insomniacs aged 29 to 83. The studies were small, mostly open-label, given into a vein, and do not show an approved sleep-treatment schedule. | limited human dataDose from a human trial · no FDA label |
| Ipamorelin | Offered for deeper sleep based on its growth-hormone effect.Reported use only | No trial has measured sleep on this page. The two completed trials tested how quickly the gut restarted after bowel surgery, and neither beat placebo. The growth-hormone pulse is measured and real; sleep was never an endpoint. | Human trialDose from a human trial · no FDA label |
| CJC-1295 | Sold for sleep, including in combinations with ipamorelin.Reported use only | The cited studies sampled growth hormone and IGF-I, including overnight blood measurements. They did not measure sleep quality. They used the long-acting form with a drug-affinity complex. | limited human dataDose from a human trial · no FDA label |
| Sermorelin | Sold by wellness clinics for sleep quality, alongside energy and body composition.Reported use only | Its trials measured height velocity in children and hormone levels in older men. Neither measured sleep. The adult study ran 14 days, so it does not answer long-term sleep questions. | limited human dataDose from a human trial · no FDA label |
| Epitalon | Sought for sleep and age-related changes in the body clock.Reported use only | One of its two human studies did measure a melatonin marker in urine and three clock genes, in 75 women over twenty days. That is circadian signaling, not sleep. That study did not report how participants slept. | limited human dataDose from a human trial · no FDA label |
DSIP has direct sleep measurements, with important limits
The cited DSIP studies date from the 1980s. One followed 18 people with chronic insomnia in a sleep laboratory and reported improvement after intravenous dosing.
These small studies do not show the effect of injecting DSIP under the skin. The quantity, route and study design need to stay with the reported result.
FDA listed emideltide, another name for DSIP, for a compounding-committee review in July 2026. A committee review is not a drug approval or proof that a treatment works.
Hormone readings are not sleep outcomes
The growth-hormone studies do not show a sleep benefit for ipamorelin, CJC-1295 or sermorelin. The Epitalon study measured a melatonin marker and clock genes, not sleep quality.
The sources on these four records do not report a sleep endpoint. That leaves the effect on sleep uncertain; it does not demonstrate either a benefit or a lack of benefit.
Where to go next
The grid of 32 compounds against 10 goals
DSIP without an approved label: what exists instead
Epitalon research, dosing, and approval status
Where the testosterone evidence stops
Where the skin evidence stops
What ipamorelin is, how it is used, and what has been studied
What CJC-1295 is, how it is used, and what has been studied
Sermorelin without an approved label: what exists instead
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805retrieved 2026-08-12Human trial
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-7retrieved 2026-08-12Human trial
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or saferetrieved 2026-08-12indirect evidence
- NCT01280344 — Phase II double-blind placebo-controlled dose-finding study of ipamorelin for recovery of gastrointestinal function after small or large bowel resection (Helsinn Therapeutics; 320 patients; arms 0.03 mg/kg BID, 0.06 mg/kg BID, 0.06 mg/kg TID, all intravenous)retrieved 2026-08-12Human trial
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527-34retrieved 2026-08-12Human trial
- Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group). J Clin Endocrinol Metab 1996;81(3):1189-96retrieved 2026-08-12Human trial
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75(2):530-5retrieved 2026-08-12Human trial
- NCT00324064 — Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing (protocol: GHRH [Geref] 1 mcg/kg intravenous push, followed by arginine)retrieved 2026-08-12Human trial
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691 — an independent Medical University of Warsaw review whose Clinical Trials section reports both human studies of the tetrapeptide with their doses, enrollments and comparison groupsretrieved 2026-08-13limited human data
- Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984;23(5):358-63retrieved 2026-08-12limited human data
- Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986;25(6):448-53retrieved 2026-08-12limited human data